| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
31,804,000 |
| Market
Cap: |
845.35(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$13.85 - $26.47 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 609 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile AnaptysBio is a clinical stage biotechnology company developing immunology therapeutic product candidates focused on immune control mechanisms applicable to inflammation and immuno-oncology indications. Co.'s wholly-owned antibody programs include: imsidolimab, which inhibits the interleukin-36 receptor and is being developed for the treatment of multiple dermatological inflammatory diseases; rosnilimab, which is an anti-PD-1 agonist antibody program designed to augment PD-1 signaling via rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, which is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
668,237 |
| Total Buy Value |
$0 |
$0 |
$0 |
$14,453,966 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
153,940 |
171,792 |
185,897 |
858,303 |
| Total Sell Value |
$3,514,453 |
$3,902,662 |
$4,176,146 |
$18,726,680 |
| Total People Sold |
2 |
4 |
4 |
5 |
| Total Sell Transactions |
3 |
9 |
14 |
18 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Suria Hamza |
President, CEO |
• • – |
2019-01-14 |
4 |
OE |
$1.12 |
$44,800 |
D/D |
40,000 |
70,064 |
|
- |
|
| Londei Marco |
Chief Medical Officer |
• – – |
2018-12-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
122,500 |
22,377 |
|
- |
|
| Londei Marco |
Chief Medical Officer |
• – – |
2018-12-17 |
4 |
AS |
$65.36 |
$2,005,856 |
D/D |
(30,048) |
144,877 |
|
- |
|
| Londei Marco |
Chief Medical Officer |
• – – |
2018-12-17 |
4 |
OE |
$0.70 |
$158,094 |
D/D |
30,048 |
174,925 |
|
- |
|
| Suria Hamza |
President, CEO |
• • – |
2018-12-14 |
4 |
AS |
$68.89 |
$2,894,375 |
D/D |
(41,728) |
30,064 |
|
- |
|
| Suria Hamza |
President, CEO |
• • – |
2018-12-14 |
4 |
OE |
$1.12 |
$46,735 |
D/D |
41,728 |
71,792 |
|
- |
|
| Suria Hamza |
President, CEO |
• • – |
2018-12-12 |
4 |
AS |
$71.11 |
$2,155,817 |
D/D |
(30,000) |
30,064 |
|
- |
|
| Suria Hamza |
President, CEO |
• • – |
2018-12-12 |
4 |
OE |
$1.12 |
$33,600 |
D/D |
30,000 |
60,064 |
|
- |
|
| Suria Hamza |
President, CEO |
• • – |
2018-12-11 |
4 |
AS |
$70.83 |
$354,008 |
D/D |
(4,998) |
30,064 |
|
- |
|
| Suria Hamza |
President, CEO |
• • – |
2018-12-10 |
4 |
AS |
$70.57 |
$2,177,588 |
D/D |
(30,587) |
35,062 |
|
- |
|
| Suria Hamza |
President, CEO |
• • – |
2018-12-10 |
4 |
OE |
$1.12 |
$34,257 |
D/D |
30,587 |
65,649 |
|
- |
|
| Piscitelli Dominic |
Chief Financial Officer |
• – – |
2018-12-03 |
4 |
AS |
$70.34 |
$2,669,158 |
D/D |
(37,000) |
0 |
|
- |
|
| Piscitelli Dominic |
Chief Financial Officer |
• – – |
2018-12-03 |
4 |
OE |
$11.34 |
$419,580 |
D/D |
37,000 |
37,000 |
|
- |
|
| Londei Marco |
Chief Medical Officer |
• – – |
2018-09-07 |
4 |
OE |
$0.70 |
$100,000 |
D/D |
142,857 |
144,877 |
|
- |
|
| Suria Hamza |
President, CEO |
• • – |
2018-07-09 |
4 |
OE |
$1.61 |
$13,194 |
D/D |
7,636 |
35,062 |
|
- |
|
| Suria Hamza |
President, CEO |
• • – |
2018-06-08 |
4 |
OE |
$2.59 |
$58,089 |
D/D |
22,428 |
27,426 |
|
- |
|
| Heron Patrick J |
10% Owner |
– – • |
2018-05-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,372,000) |
973,612 |
|
- |
|
| Topper James N |
Director |
– • – |
2018-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
31,854 |
31,854 |
|
- |
|
| Topper James N |
Director |
– • – |
2018-05-11 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,673,024) |
0 |
|
- |
|
| Topper James N |
Director |
– • – |
2018-05-11 |
4 |
A |
$0.00 |
$0 |
I/I |
301,024 |
301,024 |
|
- |
|
| Heron Patrick J |
10% Owner |
– – • |
2018-05-11 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,372,000) |
973,612 |
|
- |
|
| Lydon Nicholas |
Director |
– • – |
2018-04-16 |
4 |
AS |
$84.18 |
$2,866,913 |
D/D |
(33,000) |
271,106 |
|
- |
|
| Lydon Nicholas |
Director |
– • – |
2018-02-15 |
4 |
OE |
$4.55 |
$74,998 |
D/D |
16,483 |
304,106 |
|
- |
|
| Novo A/s |
10% Owner |
– – • |
2017-08-21 |
4 |
S |
$21.10 |
$7,518,251 |
D/D |
(356,300) |
1,936,604 |
|
- |
|
| Novo A/s |
10% Owner |
– – • |
2017-08-15 |
4 |
S |
$21.00 |
$3,011,988 |
D/D |
(143,428) |
2,292,904 |
|
- |
|
130 Records found
|
|
Page 4 of 6 |
|
|
0.24 (0.91%) 
